The 2023 study [103] found that among individuals with biomarker evidence of non-AD pathology (suspected non-Alzheimer’s pathophysiology), those with chronic pain had higher CSF total tau and soluble triggering receptor expressed on myeloid cells 2 (sTREM2) (a microglial activation marker) than those without pain. The gene discussed is MAPT; the disease is Alzheimer disease.